Study drug use among university students in Western Australia: Results of a web survey and their policy and practice implications.
cognitive enhancers
contextual factors
prevalence
study drugs
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
07
09
2020
received:
04
05
2020
accepted:
14
09
2020
pubmed:
16
11
2020
medline:
27
11
2021
entrez:
15
11
2020
Statut:
ppublish
Résumé
Recent research and anecdotal reports suggest increased use of 'study drugs' or cognitive enhancers (CE) by university students. Evidence suggests students who use CEs tend to perceive them as effective, but whether CEs improve cognition in healthy individuals is unclear and any drug use carries a risk of harm. Two previous studies have investigated the prevalence of use in Australian university student samples and neither assessed university system factors which may contribute to use. During 2016, a convenience sample of 2133 18-29-year-old students across all five Western Australian universities completed a quantitative anonymous web survey targeting both users and non-users of CE. Of the final sample, 7.9% reported use of a prescription drug for CE purposes in the last 12 months. Prescription CE use was predicted by greater frequency of illicit drug use and among students who reported they had not had a take-home exam in the last 12 months. Rates of use and predictors of over the counter (28.6%) and illicit drugs (2.4%) were predicted by different individual and contextual factors. There were high rates of reporting positive effects from CE use, but although negative effects were reported less commonly, they were not trivial. These findings have implications for university policy and university health services raising the issue with students and potentially providing clinical interventions addressing CE use. Further research should include representative samples and address both system and individual variables in understanding patterns of CE use among students.
Substances chimiques
Illicit Drugs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
530-539Informations de copyright
© 2020 Australasian Professional Society on Alcohol and other Drugs.
Références
Smith ME, Farah MJ. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull 2011;137:717-41.
Malykh A, Sadaie M. Piracetam and Piracetam-like drugs from basic science to novel clinical applications to CNS disorders. Drugs 2010;70:287-312.
Ragan C, Bard I, Singh I. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 2013;64:588-95.
Repantis D, Maier LJ, Heuser I. Correspondence arising: Modafinil for cognitive neuroenhancement in health non-sleep-deprived-subjects. Eur Neuropsychopharmacol 2016;26:392-3.
Nicholson PJ. Correspondence arising: Modafinil for cognitive neuroenhancement in health non-sleep-deprived-subjects. Eur Neuropsychopharmacol 2016;26:390.
Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur Neuropsychopharmacol 2016;26:391.
Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010;62:187-206.
Logan AC. Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids Health Dis 2004;3:25.
Gilleen J, Michalopoulou PG, Reichenberg A et al. Modafinil combined with cognitive training is associated with improved learning in healthy volunteers - a randomised controlled trial. Eur Neuropsychopharmacol 2014;24:529-39.
Franke AG, Gränsmark P, Agricola A et al. Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: a double-blind, randomised controlled trial. Eur Neuropsychopharmacol 2017;27:248-60.
Arria AM, Caldeira KM, Vincent KB et al. Do college students improve their grades by using prescription stimulants nonmedically? Addict Behav 2017;65:245-9.
d'Angelo LSC, Savulich G, Sahakian BJ. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br J Pharmacol 2017;174:3257-67.
Aikins R, Zhang X, McCabe SE. Academic doping: institutional policies regarding nonmedical use of prescription stimulants in U.S. higher education. J Acad Ethics 2017;15:229-43.
Oskooilar N. A case of premature ventricular contractions with modafinil. Am J Psychiatry 2005;162:1983-4.
Paliza J. Use of cognitive enhancing substances by university students: a cross-sectional study. Australia: Curtin University, 2011.
U.S. Food and Drug Administration. Counterfeit Drugs Questions and Answers. Washington: FDA, 2013.
DuPont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict 2008;17:167-71.
Desantis A, Noar SM, Webb EM. Nonmedical ADHD stimulant use in fraternities. J Stud Alcohol Drugs 2009;70:952-4.
Lucke J, Jensen C, Dunn M et al. Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use. BMC Public Health 2018;18:1270.
Mazanov J, Dunn M, Connora J, Fielding M-L. Substance use to enhance academic performance among Australian university students. Perform Enhanc Health 2013;2:110-8.
Ram S, Hussainy S, Henning M, Jensen M, Russell B. Prevalence of cognitive enhancer use among New Zealand tertiary students. Drug Alcohol Rev 2016;35:345-51.
Micoulaud-Franchi JA, Macgregor A, Fond G. A preliminary study on cognitive enhancer consumption behaviors and motives of French medicine and pharmacology students. Eur Rev Med Pharmacol Sci 2014;18:1875-8.
Maier LJ, Ferris JA, Winstock AR. Pharmacological cognitive enhancement among non-ADHD individuals-a cross-sectional study in 15 countries. Int J Drug Policy 2018;58:104-12.
Mousavi F, Shojaei P, Markeh HP. The use of cognitive enhancers among medical students. Int J High Risk Behav Addict 2019;8:e92377.
Jensen C, Forlini C, Partridge B, Hall W. Australian university students' coping strategies and use of pharmaceutical stimulants as cognitive enhancers. Front Psychol 2016;7:277.
Sattler S. Nonmedical use of prescription drugs for cognitive enhancement as response to chronic stress especially when social support is lacking. Stress Health 2019;35:127-37.
Liakoni E, Schaub MP, Maier LJ, Glauser GV, Liechti ME. The use of prescription drugs, recreational drugs, and "soft enhancers" for cognitive enhancement among swiss secondary school students. PLoS ONE 2015;10:e0141289.
Maier LJ, Haug S, Schaub MP. Prevalence of and motives for pharmacological neuroenhancement in Switzerland-results from a national internet panel. Addiction 2016;111:280-95.
Teter CJ, DiRaimo CG, West BT, Schepis TS, McCabe SE. Nonmedical use of prescription stimulants among US high school students to help study: results from a national survey. J Pharm Pract 2020;33:38-47.
De Bruyn S, Wouters E, Ponnet K, Van Hal G. Popping smart pills in medical school: are competition and stress associated with the misuse of prescription stimulants among students? Subst Use Misuse 2019;54:1191-202.
Petersen MA, Enghoff O, Demant J. The uncertainties of enhancement: a mixed-methods study on the use of substances for cognitive enhancement and it's unintended consequences. Perform Enhanc Health 2019;6:111-20.
Volkow ND, Fowler JS, Logan J et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54.
IBM Corporation. IBM SPSS statistics 25. Armonk, NY: IBM Corporation, 2017.
Whilely M, Allsop S. Look west for Australian evidence of the relationship between amphetamine-type stimulant prescribing and meth/amphetamine use. Drug Alcohol Rev 2020;39:519-24.
Grigg J, Lenton S, Western Australian Drug Trends. Key findings from the ecstasy and related drugs reporting system (EDRS) interviews. UNSW Sydney: Sydney National Drug and Alcohol Research Centre, 2019:2020.
Peacock A, Karlsson A, Uporova J et al. Australian drug trends 2019: key findings from the National Ecstasy and related drugs reporting system (EDRS) interviews. Sydney: National Drug and Alcohol Research Centre, UNSW, 2019.
Hupli A, Didžiokaitė G, Ydema M. Beyond treatment versus enhancement: a qualitative study of pharmacological neuro-enhancement among Dutch and Lithuanian university students. Contemp Drug Probl 2019;46:379-99.
Dursun S, Dunn M, McKay FH. The availability and acquisition of modafinil on the internet. Drug Alcohol Rev 2019;38:699-702.
Bengtsson L. Take-home exams in higher education: a systematic review. Education Sciences 2019;29:267.